{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:27:36Z","timestamp":1782512856653,"version":"3.54.5"},"reference-count":94,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Prostate Cancer"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.3816\/cgc.2004.n.004","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:07:25Z","timestamp":1221095245000},"page":"228-235","source":"Crossref","is-referenced-by-count":69,"title":["Does Finasteride Alter the Pathology of the Prostate and Cancer Grading?"],"prefix":"10.3816","volume":"2","author":[{"given":"David G.","family":"Bostwick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Civantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus G.","family":"Roehrborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Montironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CGC.2004.n.004_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/canjclin.53.1.5","article-title":"Cancer statistics, 2003","volume":"53","author":"Jemal","year":"2003","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CGC.2004.n.004_bib2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/ajhp\/60.15.1511","article-title":"Finasteride may prevent prostate cancer","volume":"60","author":"Thompson","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.3816\/CGC.2004.n.004_bib3","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1097\/01.ju.0000057804.01025.13","article-title":"Re: Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk","volume":"169","author":"Jacobsen","year":"2003","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1078-1439(03)00004-8","article-title":"Hormonal prevention of prostate cancer","volume":"21","author":"Brawley","year":"2003","journal-title":"Urol Oncol"},{"key":"10.3816\/CGC.2004.n.004_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0090-4295(00)00931-6","article-title":"Executive Summary of the National Cancer Institute Workshop: Highlights and Recommendations","volume":"57","author":"Lieberman","year":"2001","journal-title":"Urology"},{"key":"10.3816\/CGC.2004.n.004_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0090-4295(00)00943-2","article-title":"Androgen antagonists: Potential role in prostate cancer prevention","volume":"57","author":"Trump","year":"2001","journal-title":"Urology"},{"key":"10.3816\/CGC.2004.n.004_bib7","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/S0022-5347(02)80349-4","article-title":"The effect of finasteride in men with benign prostatic hyperplasia, 1992","volume":"167","author":"Gormley","year":"2002","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib8","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0090-4295(98)00666-9","article-title":"Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group","volume":"53","author":"Hudson","year":"1999","journal-title":"Urology"},{"key":"10.3816\/CGC.2004.n.004_bib9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0090-4295(02)02548-7","article-title":"Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia","volume":"61","author":"Lowe","year":"2003","journal-title":"Urology"},{"key":"10.3816\/CGC.2004.n.004_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003495-199346010-00010","article-title":"Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia","volume":"46","author":"Peters","year":"1993","journal-title":"Drugs"},{"key":"10.3816\/CGC.2004.n.004_bib11","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0090-4295(02)01971-4","article-title":"Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia","volume":"60","author":"Vaughan","year":"2002","journal-title":"Urology"},{"key":"10.3816\/CGC.2004.n.004_bib12","first-page":"1","article-title":"Finasteride effect on benign prostatic hyperplasia and prostate cancer. A comparative clinico-pathologic study of radical prostatectomies","volume":"6","author":"Civantos","year":"1997","journal-title":"J Urol Pathol"},{"key":"10.3816\/CGC.2004.n.004_bib13","first-page":"461","article-title":"Evaluation of prostatic intraepithelial neoplasia after treatment with a 5-alpha-reductase inhibitor (finasteride). A methodologic approach","volume":"18","author":"Montironi","year":"1996","journal-title":"Anal Quant Cytol Histol"},{"key":"10.3816\/CGC.2004.n.004_bib14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0090-4295(98)00579-2","article-title":"Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study","volume":"53","author":"Yang","year":"1999","journal-title":"Urology"},{"key":"10.3816\/CGC.2004.n.004_bib15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/A:1015531326689","article-title":"Contribution of the androgen receptor to prostate cancer predisposition and progression","volume":"20","author":"Buchanan","year":"2001","journal-title":"Cancer Metastasis Rev"},{"key":"10.3816\/CGC.2004.n.004_bib16","first-page":"277","article-title":"Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence","volume":"2","author":"Tilley","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CGC.2004.n.004_bib17","first-page":"267","article-title":"Studies on androgen receptor mutations and amplification in human prostate cancer","volume":"81","author":"Culig","year":"2003","journal-title":"Methods Mol Med"},{"key":"10.3816\/CGC.2004.n.004_bib18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000019918","article-title":"Mechanism of androgen receptor activation and possible implications for chemoprevention trials","volume":"35","author":"Klocker","year":"1999","journal-title":"Eur Urol"},{"key":"10.3816\/CGC.2004.n.004_bib19","first-page":"314","article-title":"Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer","volume":"57","author":"Koivisto","year":"1997","journal-title":"Cancer Res"},{"key":"10.3816\/CGC.2004.n.004_bib20","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/S0022-5347(05)66935-2","article-title":"Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer","volume":"164","author":"Palmberg","year":"2000","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib21","first-page":"11","article-title":"Total androgenic blockade: a review","volume":"63","author":"Bianchi","year":"1995","journal-title":"Acta Urol Belg"},{"key":"10.3816\/CGC.2004.n.004_bib22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<531::AID-CNCR15>3.0.CO;2-2","article-title":"A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats","volume":"82","author":"Tsukamoto","year":"1998","journal-title":"Cancer"},{"key":"10.3816\/CGC.2004.n.004_bib23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1210\/en.130.2.685","article-title":"Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response","volume":"130","author":"Lamb","year":"1992","journal-title":"Endocrinology"},{"key":"10.3816\/CGC.2004.n.004_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/(SICI)1097-0045(19980515)35:3<157::AID-PROS1>3.0.CO;2-E","article-title":"Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor","volume":"35","author":"Prahalada","year":"1998","journal-title":"Prostate"},{"key":"10.3816\/CGC.2004.n.004_bib25","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/0090-4295(94)90184-8","article-title":"Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5-alpha reductase inhibitor","volume":"43","author":"Prahalada","year":"1994","journal-title":"Urology"},{"key":"10.3816\/CGC.2004.n.004_bib26","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1210\/en.136.2.741","article-title":"Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride","volume":"136","author":"Rittmaster","year":"1995","journal-title":"Endocrinology"},{"key":"10.3816\/CGC.2004.n.004_bib27","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1172\/JCI119074","article-title":"Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat","volume":"98","author":"Wright","year":"1996","journal-title":"J Clin Invest"},{"key":"10.3816\/CGC.2004.n.004_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00005392-200101000-00081","article-title":"Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride","volume":"165","author":"Shibata","year":"2001","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2460\/ajvr.2002.63.495","article-title":"Finasteride-induced prostatic involution by apoptosis in dogs with benign prostatic hypertrophy","volume":"63","author":"Sirinarumitr","year":"2002","journal-title":"Am J Vet Res"},{"key":"10.3816\/CGC.2004.n.004_bib30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/pros.2990270302","article-title":"Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-alpha reductase inhibitors","volume":"27","author":"Laroque","year":"1995","journal-title":"Prostate"},{"key":"10.3816\/CGC.2004.n.004_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/pros.2990240207","article-title":"Effects of chronic oral administration of a selective 5 alpha-reductase inhibitor, finasteride, on the dog prostate","volume":"24","author":"Laroque","year":"1994","journal-title":"Prostate"},{"key":"10.3816\/CGC.2004.n.004_bib32","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1210\/en.133.2.904","article-title":"Effect of combination treatment with zanoterone (WIN 49596), a steroidal androgen receptor antagonist, and finasteride (MK-906), a steroidal 5 alpha-reductase inhibitor, on the prostate and testes of beagle dogs","volume":"133","author":"Juniewicz","year":"1993","journal-title":"Endocrinology"},{"key":"10.3816\/CGC.2004.n.004_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pros.2990170204","article-title":"Effects of androgen and antiandrogen treatment on canine prostatic arginine esterase","volume":"17","author":"Juniewicz","year":"1990","journal-title":"Prostate"},{"key":"10.3816\/CGC.2004.n.004_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/pros.2990260202","article-title":"Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression","volume":"26","author":"Cohen","year":"1995","journal-title":"Prostate"},{"key":"10.3816\/CGC.2004.n.004_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mrm.1910210109","article-title":"Magnetic resonance imaging of the efficacy of specific inhibition of 5 alpha-reductase in canine spontaneous benign prostatic hyperplasia","volume":"21","author":"Cohen","year":"1991","journal-title":"Magn Reson Med"},{"key":"10.3816\/CGC.2004.n.004_bib36","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1210\/jc.81.2.814","article-title":"Evidence for atrophy and apoptosis in the prostates of men given finasteride","volume":"81","author":"Rittmaster","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3816\/CGC.2004.n.004_bib37","first-page":"123","article-title":"Morphologic changes in benign prostatic hyperplasia following chronic treatment with the 5-alpha-Reductase inhibitor Finasteride","volume":"4","author":"Montironi","year":"1996","journal-title":"J Urol Pathol"},{"key":"10.3816\/CGC.2004.n.004_bib38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/jcp.49.4.324","article-title":"Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond","volume":"49","author":"Montironi","year":"1996","journal-title":"J Clin Pathol"},{"key":"10.3816\/CGC.2004.n.004_bib39","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/S0022-5347(01)64707-4","article-title":"Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia","volume":"157","author":"Marks","year":"1997","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/(SICI)1097-0045(19981001)37:2<84::AID-PROS4>3.0.CO;2-L","article-title":"Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-beta receptor expression","volume":"37","author":"Saez","year":"1998","journal-title":"Prostate"},{"key":"10.3816\/CGC.2004.n.004_bib41","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0090-4295(98)00567-6","article-title":"Long-term effects of finasteride on prostate tissue composition","volume":"53","author":"Marks","year":"1999","journal-title":"Urology"},{"key":"10.3816\/CGC.2004.n.004_bib42","first-page":"63","article-title":"Nodular hyperplasia of the prostate. Quantitative evaluation of secretory cell changes after treatment with finasteride","volume":"21","author":"Pomante","year":"1999","journal-title":"Anal Quant Cytol Histol"},{"key":"10.3816\/CGC.2004.n.004_bib43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/(SICI)1097-0045(20000215)42:3<203::AID-PROS6>3.0.CO;2-Y","article-title":"Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5","volume":"42","author":"Thomas","year":"2000","journal-title":"Prostate"},{"key":"10.3816\/CGC.2004.n.004_bib44","first-page":"161","article-title":"Effect of LHRH agonist and flutamide (combination endocrine therapy) on the frequency and location of Proliferating Cell Nuclear Antigen and apoptotic bodies in benign prostatic hyperplasia","volume":"2","author":"Montironi","year":"1994","journal-title":"J Urol Pathol"},{"key":"10.3816\/CGC.2004.n.004_bib45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/1097-0045(200101)46:1<45::AID-PROS1007>3.0.CO;2-U","article-title":"Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia","volume":"46","author":"Glassman","year":"2001","journal-title":"Prostate"},{"key":"10.3816\/CGC.2004.n.004_bib46","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0022-5347(05)65188-9","article-title":"Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia","volume":"167","author":"Hochberg","year":"2002","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0022-5347(05)64025-6","article-title":"The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients","volume":"169","author":"Pareek","year":"2003","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib48","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pros.2990220403","article-title":"Finasteride (MK-906) in the treatment of benign prostatic hyperplasia","volume":"22","author":"The Finasteride Study Group","year":"1993","journal-title":"Prostate"},{"key":"10.3816\/CGC.2004.n.004_bib49","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0090-4295(95)80019-0","article-title":"Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro","volume":"45","author":"Bologna","year":"1995","journal-title":"Urology"},{"key":"10.3816\/CGC.2004.n.004_bib50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/pros.2990240503","article-title":"Effect of 5-alpha-reductase inhibition and dexamethasone administration on the growth characteristics and intratumor androgen levels of the human prostate cancer cell line PC-3","volume":"24","author":"Tuttle","year":"1994","journal-title":"Prostate"},{"key":"10.3816\/CGC.2004.n.004_bib51","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0022-5347(17)42657-7","article-title":"Aromatase inhibition in the dog. II. Effect on growth, function, and pathology of the prostate","volume":"139","author":"Oesterling","year":"1988","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib52","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00000478-199601000-00010","article-title":"Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostate carcinoma. A randomized study","volume":"20","author":"Vaillancourt","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"10.3816\/CGC.2004.n.004_bib53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0090-4295(94)80015-4","article-title":"Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy","volume":"44","author":"Ferguson","year":"1994","journal-title":"Urology"},{"key":"10.3816\/CGC.2004.n.004_bib54","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0344-0338(11)80971-4","article-title":"Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation","volume":"191","author":"Montironi","year":"1995","journal-title":"Pathol Res Pract"},{"key":"10.3816\/CGC.2004.n.004_bib55","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/jcp.47.10.906","article-title":"Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma","volume":"47","author":"Montironi","year":"1994","journal-title":"J Clin Pathol"},{"key":"10.3816\/CGC.2004.n.004_bib56","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00000478-199102000-00002","article-title":"Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study","volume":"15","author":"Tetu","year":"1991","journal-title":"Am J Surg Pathol"},{"key":"10.3816\/CGC.2004.n.004_bib57","first-page":"36","article-title":"Prostate adenocarcinoma after androgen deprivation therapy: A comparative study of morphology, morphometry, immunohistochemistry, and DNA ploidy","volume":"2","author":"Ellison","year":"1996","journal-title":"Pathol Care Reviews"},{"key":"10.3816\/CGC.2004.n.004_bib58","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0344-0338(80)80211-1","article-title":"Histologic grading of prostatic carcinoma","volume":"168","author":"Bocking","year":"1980","journal-title":"Pathol Res Pract"},{"key":"10.3816\/CGC.2004.n.004_bib59","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<376::AID-CNCR32>3.0.CO;2-R","article-title":"Assessment of prostate carcinoma in core needle biopsy\u2013definition of minimal criteria for the diagnosis of cancer in biopsy material","volume":"78","author":"Algaba","year":"1996","journal-title":"Cancer"},{"key":"10.3816\/CGC.2004.n.004_bib60","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/00000478-199410000-00002","article-title":"Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma","volume":"18","author":"Armas","year":"1994","journal-title":"Am J Surg Pathol"},{"key":"10.3816\/CGC.2004.n.004_bib61","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00000478-198209000-00006","article-title":"Radiation injury of the normal and neoplastic prostate","volume":"6","author":"Bostwick","year":"1982","journal-title":"Am J Surg Pathol"},{"key":"10.3816\/CGC.2004.n.004_bib62","first-page":"3091","article-title":"Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping","volume":"56","author":"Cher","year":"1996","journal-title":"Cancer Res"},{"key":"10.3816\/CGC.2004.n.004_bib63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1097-0045(199608)29:2<117::AID-PROS7>3.0.CO;2-C","article-title":"Molecular biology of prostatic intraepithelial neoplasia","volume":"29","author":"Bostwick","year":"1996","journal-title":"Prostate"},{"key":"10.3816\/CGC.2004.n.004_bib64","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1464-410X.2002.02982.x","article-title":"Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial","volume":"90","author":"Aus","year":"2002","journal-title":"BJU Int"},{"key":"10.3816\/CGC.2004.n.004_bib65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0090-4295(01)01245-6","article-title":"Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer","volume":"58","author":"Meyer","year":"2001","journal-title":"Urology"},{"key":"10.3816\/CGC.2004.n.004_bib66","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0022-5347(05)65393-1","article-title":"Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results","volume":"167","author":"Soloway","year":"2002","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib67","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/01.ju.0000081404.98273.fd","article-title":"Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy","volume":"170","author":"Klotz","year":"2003","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib68","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0022-5347(17)43413-6","article-title":"Proteins of the rat prostate. II. Synthesis of new proteins in the ventral lobe during castration-induced regression","volume":"138","author":"Lee","year":"1987","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib69","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00048064","article-title":"Active cell death in hormone-dependent tissues","volume":"11","author":"Tenniswood","year":"1992","journal-title":"Cancer Metastasis Rev"},{"key":"10.3816\/CGC.2004.n.004_bib70","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0022-5347(01)65749-5","article-title":"Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy","volume":"156","author":"Kruithof-Dekker","year":"1996","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib71","first-page":"3438","article-title":"Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer","volume":"8","author":"Di Lorenzo","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CGC.2004.n.004_bib72","first-page":"2643","article-title":"HER-2\/neu (p185neu) protein expression in the natural or treated history of prostate cancer","volume":"7","author":"Osman","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CGC.2004.n.004_bib73","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.10339","article-title":"HER-2 profiling and targeting in prostate carcinoma","volume":"94","author":"Morris","year":"2002","journal-title":"Cancer"},{"key":"10.3816\/CGC.2004.n.004_bib74","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/jnci\/92.23.1918","article-title":"Her-2-neu expression and progression toward androgen independence in human prostate cancer","volume":"92","author":"Signoretti","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CGC.2004.n.004_bib75","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0022-5347(05)65822-3","article-title":"Her-2\/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease","volume":"166","author":"Shi","year":"2001","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib76","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/S0022-5347(01)66113-5","article-title":"NM23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: altered expression in combined androgen blockaded carcinomas","volume":"155","author":"Borchers","year":"1996","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib77","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/01.ju.0000051580.89109.4b","article-title":"Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site","volume":"169","author":"Kauffman","year":"2003","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib78","first-page":"3823","article-title":"Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters","volume":"20","author":"Stravodimos","year":"2000","journal-title":"Anticancer Res"},{"key":"10.3816\/CGC.2004.n.004_bib79","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0090-4295(02)02061-7","article-title":"Glycoprotein A-80 in the human prostate: immunolocalization in prostatic intraepithelial neoplasia, carcinoma, radiation failure, and after neoadjuvant hormonal therapy","volume":"61","author":"Coogan","year":"2003","journal-title":"Urology"},{"key":"10.3816\/CGC.2004.n.004_bib80","first-page":"390","article-title":"Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers","volume":"143","author":"Colombel","year":"1993","journal-title":"Am J Pathol"},{"key":"10.3816\/CGC.2004.n.004_bib81","first-page":"4438","article-title":"Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo","volume":"55","author":"Raffo","year":"1995","journal-title":"Cancer Res"},{"key":"10.3816\/CGC.2004.n.004_bib82","first-page":"1539","article-title":"Androgens regulate the expression of proliferating cell nuclear antigen posttranscriptionally in the human prostate cancer cell line, LNCaP","volume":"56","author":"Perry","year":"1996","journal-title":"Cancer Res"},{"key":"10.3816\/CGC.2004.n.004_bib83","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/S0022-5347(17)36446-7","article-title":"Treatment of prostatic bleeding: suppression of angiogenesis by androgen deprivation","volume":"149","author":"Marshall","year":"1993","journal-title":"J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib84","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/1097-0045(20000915)45:1<72::AID-PROS9>3.0.CO;2-U","article-title":"Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients","volume":"45","author":"Mazzucchelli","year":"2000","journal-title":"Prostate"},{"key":"10.3816\/CGC.2004.n.004_bib85","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/03008880310006904","article-title":"New principles in the treatment of hormonal refractory prostate cancer","author":"Nisen","year":"2003","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"10.3816\/CGC.2004.n.004_bib86","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0002-9440(10)61676-8","article-title":"Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma","volume":"159","author":"Leav","year":"2001","journal-title":"Am J Pathol"},{"key":"10.3816\/CGC.2004.n.004_bib87","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/1097-0045(199609)29:3<137::AID-PROS2990290302>3.0.CO;2-Z","article-title":"Androgen receptor expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human prostate: an immunohistochemical and in situ hybridization study","volume":"29","author":"Leav","year":"1996","journal-title":"Prostate"},{"key":"10.3816\/CGC.2004.n.004_bib88","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0090-4295(00)01052-9","article-title":"Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens","volume":"57","author":"Marks","year":"2001","journal-title":"Urology"},{"key":"10.3816\/CGC.2004.n.004_bib89","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s003450000159","article-title":"Prostatic expression of human 5alpha-reductase type 2 during finasteride therapy: a randomized, double-blind, placebo-controlled study","volume":"18","author":"Vaarala","year":"2000","journal-title":"World J Urol"},{"key":"10.3816\/CGC.2004.n.004_bib90","first-page":"191","article-title":"Target populations and strategies for chemoprevention trials of prostate cancer","volume":"19","author":"Bostwick","year":"1994","journal-title":"J Cell Biochem Suppl"},{"key":"10.3816\/CGC.2004.n.004_bib91","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/(SICI)1097-4644(1996)25+<156::AID-JCB22>3.0.CO;2-L","article-title":"Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials","volume":"25","author":"Bostwick","year":"1996","journal-title":"J Cell Biochem Suppl"},{"key":"10.3816\/CGC.2004.n.004_bib92","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/978-3-642-55647-0_19","article-title":"Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial","volume":"163","author":"Klein","year":"2003","journal-title":"Recent Results Cancer Res"},{"key":"10.3816\/CGC.2004.n.004_bib93","first-page":"199","article-title":"Intermediate biomarkers for chemoprevention of prostate cancer","volume":"154","author":"van der Kwast","year":"2001","journal-title":"IARC Sci Publ"},{"key":"10.3816\/CGC.2004.n.004_bib94","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Clinical Prostate Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1540035211700506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1540035211700506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T22:59:44Z","timestamp":1557788384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1540035211700506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":94,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S1540035211700506"],"URL":"https:\/\/doi.org\/10.3816\/cgc.2004.n.004","relation":{},"ISSN":["1540-0352"],"issn-type":[{"value":"1540-0352","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}